Cargando…

Platelets, diabetes and myocardial ischemia/reperfusion injury

Mechanisms underlying the pathogenesis of ischemia/reperfusion injury are particularly complex, multifactorial and highly interconnected. A complex and entangled interaction is also emerging between platelet function, antiplatelet drugs, coronary diseases and ischemia/reperfusion injury, especially...

Descripción completa

Detalles Bibliográficos
Autores principales: Russo, Isabella, Penna, Claudia, Musso, Tiziana, Popara, Jasmin, Alloatti, Giuseppe, Cavalot, Franco, Pagliaro, Pasquale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452354/
https://www.ncbi.nlm.nih.gov/pubmed/28569217
http://dx.doi.org/10.1186/s12933-017-0550-6
_version_ 1783240397030424576
author Russo, Isabella
Penna, Claudia
Musso, Tiziana
Popara, Jasmin
Alloatti, Giuseppe
Cavalot, Franco
Pagliaro, Pasquale
author_facet Russo, Isabella
Penna, Claudia
Musso, Tiziana
Popara, Jasmin
Alloatti, Giuseppe
Cavalot, Franco
Pagliaro, Pasquale
author_sort Russo, Isabella
collection PubMed
description Mechanisms underlying the pathogenesis of ischemia/reperfusion injury are particularly complex, multifactorial and highly interconnected. A complex and entangled interaction is also emerging between platelet function, antiplatelet drugs, coronary diseases and ischemia/reperfusion injury, especially in diabetic conditions. Here we briefly summarize features of antiplatelet therapy in type 2 diabetes (T2DM). We also treat the influence of T2DM on ischemia/reperfusion injury and how anti-platelet therapies affect post-ischemic myocardial damage through pleiotropic properties not related to their anti-aggregating effects. miRNA-based signature associated with T2DM and its cardiovascular disease complications are also briefly considered. Influence of anti-platelet therapies and different effects of healthy and diabetic platelets on ischemia/reperfusion injury need to be further clarified in order to enhance patient benefits from antiplatelet therapy and revascularization. Here we provide insight on the difficulty to reduce the cardiovascular risk in diabetic patients and report novel information on the cardioprotective role of widely used anti-aggregant drugs.
format Online
Article
Text
id pubmed-5452354
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54523542017-06-01 Platelets, diabetes and myocardial ischemia/reperfusion injury Russo, Isabella Penna, Claudia Musso, Tiziana Popara, Jasmin Alloatti, Giuseppe Cavalot, Franco Pagliaro, Pasquale Cardiovasc Diabetol Review Mechanisms underlying the pathogenesis of ischemia/reperfusion injury are particularly complex, multifactorial and highly interconnected. A complex and entangled interaction is also emerging between platelet function, antiplatelet drugs, coronary diseases and ischemia/reperfusion injury, especially in diabetic conditions. Here we briefly summarize features of antiplatelet therapy in type 2 diabetes (T2DM). We also treat the influence of T2DM on ischemia/reperfusion injury and how anti-platelet therapies affect post-ischemic myocardial damage through pleiotropic properties not related to their anti-aggregating effects. miRNA-based signature associated with T2DM and its cardiovascular disease complications are also briefly considered. Influence of anti-platelet therapies and different effects of healthy and diabetic platelets on ischemia/reperfusion injury need to be further clarified in order to enhance patient benefits from antiplatelet therapy and revascularization. Here we provide insight on the difficulty to reduce the cardiovascular risk in diabetic patients and report novel information on the cardioprotective role of widely used anti-aggregant drugs. BioMed Central 2017-05-31 /pmc/articles/PMC5452354/ /pubmed/28569217 http://dx.doi.org/10.1186/s12933-017-0550-6 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Russo, Isabella
Penna, Claudia
Musso, Tiziana
Popara, Jasmin
Alloatti, Giuseppe
Cavalot, Franco
Pagliaro, Pasquale
Platelets, diabetes and myocardial ischemia/reperfusion injury
title Platelets, diabetes and myocardial ischemia/reperfusion injury
title_full Platelets, diabetes and myocardial ischemia/reperfusion injury
title_fullStr Platelets, diabetes and myocardial ischemia/reperfusion injury
title_full_unstemmed Platelets, diabetes and myocardial ischemia/reperfusion injury
title_short Platelets, diabetes and myocardial ischemia/reperfusion injury
title_sort platelets, diabetes and myocardial ischemia/reperfusion injury
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452354/
https://www.ncbi.nlm.nih.gov/pubmed/28569217
http://dx.doi.org/10.1186/s12933-017-0550-6
work_keys_str_mv AT russoisabella plateletsdiabetesandmyocardialischemiareperfusioninjury
AT pennaclaudia plateletsdiabetesandmyocardialischemiareperfusioninjury
AT mussotiziana plateletsdiabetesandmyocardialischemiareperfusioninjury
AT poparajasmin plateletsdiabetesandmyocardialischemiareperfusioninjury
AT alloattigiuseppe plateletsdiabetesandmyocardialischemiareperfusioninjury
AT cavalotfranco plateletsdiabetesandmyocardialischemiareperfusioninjury
AT pagliaropasquale plateletsdiabetesandmyocardialischemiareperfusioninjury